As a leader and expert in the field of drug development for autoimmune diseases, Creative Biolabs provides state-of-art technologies to meet any requirement of our customers. We have completed a series of challenges in the past years. In particular, we have established a monoclonal antibody development targeting CD20 discovery platform which enables us to offer a series of high-quality services for treating many autoimmune diseases.
CD20, the main type of B-lymphocyte antigen, has played an important role in mediating B-cell immune responses against various antigens. Meanwhile, CD20 can be induced by chemokine signaling molecules, such as CXCL12, and can be regarded as a calcium channel in the microenvironment. In general, CD20 can be identified in all almost stages of the B cell development process, ranging from pro-B cells to memory B cells. Moreover, it is also found in a wide variety of B-cell neoplasms, including B-cell lymphomas and B-cell lymphocytic leukemia. Therefore, it should be an attractive target for diagnosing these conditions. Also, recent studies have demonstrated that B cell depletion therapy based on anti-CD20 monoclonal antibodies can be a powerful tool for revealing the essential role of CD20 and B cells in treating different autoimmune diseases, like rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), as well as multiple sclerosis (MS).
Fig.1 B cell targeting in autoimmune diseases with anti-CD20. (Radbruch, 2004)
CD20 is a transmembrane protein that plays a critical role in regulating the process of B cell activation, B cell proliferation, and B cell differentiation. Nowadays, pilot studies have shown that CD20 can exhibit decreased T-independent immune responses and can be used as a therapeutic target in the treatment of several tumors and autoimmune diseases. As a consequence, Creative Biolabs has developed a comprehensive anti-CD20 monoclonal antibody development platform targeting B cells. These antibodies can maintain long-term immune memory and rapid reconstruction of b cells after depletion. Besides, anti-CD20 monoclonal antibodies can be produced by plasma cells, and almost completely depletes peripheral B cells, but antibody levels do not decrease significantly.
Currently, we are proud to be able to create flexible based monoclonal antibody development targeting CD20 solutions for our customers. Our strong reputations are based on the successful development of various CD20 antibodies and bring them to various forms of clinical application. You will be able to access an end-to-end, fully integrated antibody-drug, and antibody product service. Meanwhile, your anti-CD20 monoclonal antibodies will be delivered on time and within budget. Our simplified supply chain and rapid development process will enable you to stay ahead in the ever-changing field of monoclonal antibody development.
In Creative Biolabs, we offer you the flexibility and speed monoclonal antibody development solutions to help you get there ahead of schedule while maintaining the highest quality. Up to now, we have a wealth of scientific knowledge in every challenge and have a track record at every stage of the monoclonal antibody development process to help you save cost and time. Furthermore, our experts understand the long and complex journey ahead of monoclonal antibody development and are as committed as you are to your success. We are driven by science and have experience solving complex CD20-based study challenges.
By continuing to grow in response to the requirements of our clients, Creative Biolabs is dedicated to exploring novel and innovative CD20-based monoclonal antibody development strategies to offer the most comprehensive, integrated portfolio of antibody discovery products and solutions. If you have any special needs in our monoclonal antibody development services or be interested in learning more about our company, please feel free to contact us for more details.
For Research Use Only | Not For Clinical Use